Histogenics Corporation (NASDAQ:HSGX)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a report issued on Thursday. They currently have a $3.50 price target on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 63.55% from the stock’s previous close.
Other analysts have also recently issued reports about the stock. Canaccord Genuity reissued a “buy” rating and set a $4.00 price target on shares of Histogenics Corporation in a research note on Friday, August 11th. Zacks Investment Research cut shares of Histogenics Corporation from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, ValuEngine cut shares of Histogenics Corporation from a “sell” rating to a “strong sell” rating in a research note on Monday, August 14th.
Histogenics Corporation (HSGX) remained flat at $$2.14 during mid-day trading on Thursday. 55,654 shares of the company traded hands, compared to its average volume of 126,500.
Histogenics Corporation (NASDAQ:HSGX) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.25) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.06. During the same quarter in the prior year, the firm earned ($0.61) EPS. equities research analysts anticipate that Histogenics Corporation will post -1.09 earnings per share for the current fiscal year.
WARNING: “Histogenics Corporation (HSGX) Stock Rating Reaffirmed by HC Wainwright” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was stolen and reposted in violation of United States & international copyright & trademark laws. The original version of this piece can be accessed at https://www.com-unik.info/2017/11/06/histogenics-corporation-hsgx-stock-rating-reaffirmed-by-hc-wainwright.html.
About Histogenics Corporation
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
What are top analysts saying about Histogenics Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Histogenics Corporation and related companies.